logo
USC and UCLA Team Up for World's First-in-Human Bladder Transplant

USC and UCLA Team Up for World's First-in-Human Bladder Transplant

Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders
Surgeons from Keck Medicine of USC and UCLA Health have performed the world's first-in-human bladder transplant. The surgery was successfully completed at Ronald Reagan UCLA Medical Center earlier this month in a joint effort by Inderbir Gill, MD, founding executive director of USC Urology, and Nima Nassiri, MD, urologic transplant surgeon and director of the UCLA Vascularized Composite Bladder Allograft Transplant Program.
'This surgery is a historic moment in medicine and stands to impact how we manage carefully selected patients with highly symptomatic 'terminal' bladders that are no longer functioning,' said Gill, who is also chair and Distinguished Professor of Urology and Shirley and Donald Skinner Chair in Urologic Cancer Surgery with the Keck School of Medicine of USC. 'Transplantation is a life-saving and life-enhancing treatment option for many conditions affecting major organs, and now the bladder can be added to the list.'
'This first attempt at bladder transplantation has been over four years in the making,' Nassiri said. 'For the appropriately selected patient, it is exciting to be able to offer a new potential option.'
Nassiri, formerly a urology resident with the Keck School and now assistant professor of urology and kidney transplantation at UCLA, and Gill worked together for several years at the Keck School to develop the new surgical technique, design a clinical trial and secure the necessary regulatory approvals.
Numerous pre-clinical procedures were performed both at Keck Medical Center of USC and OneLegacy, Southern California's organ procurement organization, to prepare for this first-in-human bladder transplant.
The patient had been dialysis-dependent for seven years. He lost the majority of his bladder during surgery to resect cancer over five years ago, leaving the remainder of his bladder too small and compromised to function appropriately. Both of his kidneys were subsequently removed due to renal cancer.
To address these deficits, Drs. Gill and Nassiri performed a combined kidney and bladder transplant, allowing the patient to immediately stop dialysis and produce urine for the first time in seven years. First, the kidney and then the bladder were transplanted. The new kidney was then connected to the new bladder. The entire procedure took approximately eight hours.
'The kidney immediately made a large volume of urine, and the patient's kidney function improved immediately,' Nassiri added. 'There was no need for any dialysis after surgery, and the urine drained properly into the new bladder.'
'Despite the complexity of the case, everything went according to plan and the surgery was successful,' said Gill. 'The patient is doing well, and we are satisfied with his clinical progress to date.'
The recovery of the kidney and bladder from the donor was performed at OneLegacy's Transplant Recovery Center in Azusa, California. All parts of the procedure, including surgery and post-surgical monitoring during the transplantation, were aligned with the highest current clinical and research standards.
Millions of people around the globe experience some degree of bladder disease and dysfunction. Some develop terminal bladders that are either non-functioning and/or cause constant pain, repeated infections and other complications. Current treatment for severe terminal cases of bladder dysfunction or a bladder that has been removed due to various conditions includes replacement or augmentation of the urinary reservoir. These surgeries use a portion of a patient's intestine to create a new bladder or a pathway for the urine to exit the body.
'While these surgeries can be effective, they come with many short- and long-term risks that compromise a patient's health, such as recurrent infections, compromised kidney function and digestive issues,' said Gill.
'A bladder transplant, on the other hand, delivers a more 'normal' urinary reservoir and may circumvent some of the challenges associated with using the intestine,' said Nassiri.
The biggest risks of organ transplant are the body's potential rejection of the organ and side effects caused by the mandatory immunosuppressive drugs given to prevent organ rejection.
'Because of the need for long-term immunosuppression, the best current candidates are those with a pre-existing organ transplant or those who need a combined kidney and bladder transplant,' said Nassiri.
As a first-in-human attempt, there are naturally many unknowns associated with the procedure, such as how well the transplanted bladder will function immediately and over time, and how much immunosuppression will ultimately be needed.
'Despite the unknowns, our goal is to understand if bladder transplantation can help patients with severely compromised bladders lead healthier lives,' said Gill.
Bladder transplants have not been done previously, in part because of the complicated vascular structure of the pelvic area and the technical complexity of the procedure. As part of the research and development stage, Gill and Nassiri successfully completed numerous practice transplantation surgeries at Keck Medical Center of USC, including the first-ever robotic bladder retrievals and successful robotic transplantations in five recently deceased donors with cardiac function maintained on ventilator support.
Several non-robotic trial runs of bladder recovery were performed at OneLegacy by Gill and Nassiri, allowing them to perfect the technique while working alongside multidisciplinary surgical teams.
The bladder transplant was done as part of a UCLA clinical trial. Gill and Nassiri hope to perform more bladder transplants together in the near future.
Under Gill's leadership, USC Urology has rapidly established itself as a pioneer and world leader in the most advanced robotic urologic oncologic surgeries for kidney, bladder, prostate, testicular and penile cancers and has achieved important milestones leveraging machine learning and artificial intelligence to optimize patient outcomes.
Information was sourced from Keck Medicine of USC. To learn more, contact mary.ferguson@med.usc.edu.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU plan would limit Chinese device makers in Europe
EU plan would limit Chinese device makers in Europe

Yahoo

time12 hours ago

  • Yahoo

EU plan would limit Chinese device makers in Europe

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. European Union member states this week voted to support a plan to adopt measures that would restrict Chinese medical device makers' access to the EU market. The member states took the action, under the EU's International Procurement Instrument, after concluding an investigation in January that looked at China's practices in the public procurement market for medical devices. The investigation found that government practices unfairly encouraged Chinese hospitals to choose domestic manufacturers' products. 'The Commission has identified measures and practices in the Chinese procurement market that lead to discrimination against EU operators and EU-made supplies,' Olof Gill, commission spokesperson, said Thursday in an emailed statement. 'This discrimination also harms both the Chinese healthcare infrastructure, which is deprived of quality equipment, and EU businesses, with a high cost in terms of jobs and economic activity in the EU.' The commission has discussed its concerns with Chinese authorities. However, a satisfactory solution has not been proposed, and the EU had no other option than to tackle the issue through an IPI investigation, Gill wrote. The commission said it could not disclose the content of the draft IPI measure or next steps in the process. Chinese manufacturers would be prohibited from bidding on public procurement contracts worth more than 5 million euros for five years. In addition, no more than 50% of a contract's value may be subcontracted to Chinese entities or include Chinese-origin medical devices, MedTech Europe said in a statement. The trade group said it would provide further updates once the IPI measures are published in the EU's official journal. The EU investigation into China's medical device procurement practices was the first use of the IPI, which was introduced in 2022. Getting fair access to Chinese markets became more challenging for medical device companies after the country launched a program calling for domestically produced medical equipment to achieve 50% market penetration in county-level hospitals by 2020 and 70% by 2025, according to a statement from the European Chamber, which represents European businesses in China. European and Chinese leaders will meet in July at a summit in Beijing. Recommended Reading EU mulls retaliation after showing China's bias against foreign device firms Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Yahoo

time21 hours ago

  • Yahoo

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule Appointment bolsters FDA approval path while company explores AI and quantum computing to enhance drug delivery platform CALABASAS, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced the appointment of Josh Neman, PhD as its new Chief Clinical Officer (CCO). Dr. Neman brings with him a distinguished career at the intersection of cancer neuroscience, translational research, and academic medicine. Dr. Neman joins NeOnc Technologies Holdings Inc. (NeOnc) from the Keck School of Medicine at the University of Southern California (USC), where he serves as Associate Professor of Neurological Surgery and Physiology & Neuroscience, and Scientific Director of the USC Brain Tumor Center. At USC, he also leads the Cancer Biology and Genomics PhD Program and serves as Director of Cancer Research Training and Education Coordination at the USC Norris Comprehensive Cancer Center- a leading National Cancer Institute-designated cancer research hospital. A nationally recognized leader in neurooncological sciences and cancer neuroscience, Dr. Neman's research has advanced the understanding of how brain microenvironments influence the progression of brain tumors and metastases. His pioneering studies on tumor-neuron interactions, GABAergic signaling in cancer, and mechanisms of leptomeningeal dissemination have helped shape new therapeutic paradigms for both adult and pediatric brain tumors. 'I am deeply honored to join NeOnc at this exciting time,' said Dr. Neman. 'NeOnc's commitment to developing innovative therapeutics, including Blood Brain Barrier-penetrant compounds like NEO212 and NEO100, aligns perfectly with my lifelong passion to improve outcomes for patients with brain tumors. I look forward to helping lead the translation of promising discoveries from the lab into meaningful clinical impact.' In his role as Chief Clinical Officer, Dr. Neman will lead NeOnc's clinical development strategy, including investigator-initiated trials and precision oncology partnerships. He will also play a key role in expanding NeOnc's research collaborations with academic institutions, regulatory agencies, and patient advocacy groups. 'Dr. Neman's appointment signals a major step forward in NeOnc's mission to transform the treatment landscape for patients with life-threatening cancers with poor outcomes,' said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, Inc. 'His academic and clinical leadership, coupled with his deep expertise in brain tumor biology, will be instrumental in accelerating all four of our clinical trials—especially our lead asset, NEO100, which is approaching the completion of its Phase 2a trial with full enrollment achieved ahead of schedule. As we look to add AI and quantum computing into our expanding platform in drug delivery and bio-conjugation, Dr. Neman's appointment further strengthens our commitment to advancing precision therapies and driving toward FDA approval.' About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): NeOnc Technologies is a publicly traded, clinical-stage biopharmaceutical company developing innovative therapies for brain and central nervous system cancers. Its lead programs—NEO100-01, NEO100-02, NEO100-03, and NEO212—utilize proprietary formulations to bypass the blood-brain barrier and target malignancies with precision. The company's IP portfolio includes 176 patents worldwide, reflecting a broad platform with strong commercialization potential. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward-Looking Statements All statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as "projected," "expect," "possibility" and "anticipate," or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law. 'NEO100' is a registered trademark of NeOnc Technologies Holdings, Inc. Company Contact:23975 Sorrento Park Suite 205, Calabasas, CA, 91302info@ Investor Relations:James CarbonaraHayden IR369 Lexington AvenueSecond FloorNew York, NY 10017Office: (646)-755-7412James@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Will Trump Torch L.A.'s Olympics?
Will Trump Torch L.A.'s Olympics?

Yahoo

time2 days ago

  • Yahoo

Will Trump Torch L.A.'s Olympics?

Just how severely Donald Trump may impact, tarnish or otherwise undermine Los Angeles' 2028 Olympic Games remains an open question. But it's now fair to expect the city's road to gold and glory will be littered with political potholes. His administration's hard-line immigration approach, extreme cost-cutting of federal services and adversarial international relations are at odds with the ethos of the mega-spectacle, which (no matter how much you buy it) bills itself as a beacon of kumbaya globalism. More from The Hollywood Reporter Seth Meyers on Finding Joy (and Comedy) in Trump's Second Term Trump Biopic 'The Apprentice' Dominates Politically Charged Canadian Screen Awards Would Trump Pardon Sean "Diddy" Combs? "I Would Certainly Look at the Facts," President Says Trump himself has in recent months reportedly assured the local Olympic organizing committee, LA28, at a private Mar-a-Lago conclave that he'll be 'supportive in every way possible' because, after all, 'these are America's Olympics.' Still, experts are sounding alarm bells. They warn that the event — taking place at the end of Trump's second term — could be a historic embarrassment for the U.S. because of his policies, which have antagonized allies as well as adversaries around the world. Jonathan Aronson, a USC professor specializing in international policy, sees a real possibility of diplomatic boycotts on the horizon: 'If he alienates other countries too much, what greater insult is there than not to come at all?' Trump's hot-button tariffs likely won't affect the costs of the Los Angeles Games, which has pledged a 'no-build' strategy that relies heavily on existing infrastructure. But visa issues may plague the lead-up to the event — and not just for athletes but the vast Olympics ecosystem, from coaches and families to sponsors and vendors to, of course, attendees. In February, the U.S. Travel Association raised concern about processing visas ahead of America's 'global events,' including the 2028 Games, in a report it commissioned from a group of former high-level officials at the Department of Homeland Security, the Transportation Security Administration and the Customs and Border Protection agency. For his part, LA28 chair Casey Wasserman, the entertainment and sports management mogul, guaranteed the International Olympic Committee in a March speech that 'irrespective of politics today, America will be open and accepting' to all countries for the Olympics. 'L.A. is the most diverse city in the history of humanity, and we will welcome the people from around the world and give them all a great time.' He added that visas will be handled by a designated desk at the State Department. 'In my many conversations with President Trump and Secretary [Marco] Rubio, they understand the scale and complexity required to deliver these Games, the access required for not just athletes but for delegations, and the incredibly short time frame on which to do those.' LA28 did not comment for this story. Others are less sanguine. 'Without additional resources, visa processing delays seem likely,' says Emma Prodromou, global visa and immigration manager at the U.K.-based workforce management consultancy Mauve Group. She explains it's 'a real concern, especially given how often complications arise from time-sensitive documents or strict administrative requirements — such as whether an abridged birth certificate is acceptable, or if a police clearance must be issued within 90 days of travel. These small but critical details can easily disrupt travel plans.' Karine Faure Wenger, who serves as corporate immigration counsel at the international law firm Fragomen, describes the situation as 'very fluid,' noting that 'the extreme enhanced vetting and screening of who is entering the U.S. will make these Games different — although President Trump is going to want the event to be a success, so I'd imagine accommodations will be made.' She also points out that there are countries participating in the Olympics with whom the U.S. doesn't have diplomatic relations, like North Korea and Iran. 'What kinds of concessions will this administration make in those situations?' The 2026 FIFA World Cup — jointly held by the U.S., Canada and Mexico — is widely considered to be a test run for the 2028 Games. FIFA president Gianni Infantino, who's close to Trump, tells The Hollywood Reporter he's 'not worried at all' about America's ongoing diplomacy tensions, including with its next-door neighbors and co-hosts. 'Next year there will be an invasion of America — but an invasion of people who come to celebrate with a positive spirit,' he says. 'From that perspective, I am sure everything will run smoothly. Of course, there are many people behind the scenes working very hard to make sure everything goes smoothly, so we can welcome the world to America.' Both the World Cup and the Olympics are designated National Special Security Events, in which the U.S. Secret Service is the lead agency in charge, along with the FBI and the Department of Homeland Security. 'This will give Trump and his administration a lot of leverage over state and local officials,' explains Pacific University professor Jules Boykoff, one of the foremost scholars on the politics of the Olympics. 'ICE will have free reign.' L.A. Mayor Karen Bass and other local politicians asked Trump in November for $3.2 billion to fund transportation projects ahead of the Games. Much of the request is to double the current fleet of buses to handle the expected millions of ticket holders. L.A. City Councilman Hugo Soto-Martinez — who, before his 2022 election, was an organizer with the activist group NOlympics LA, which called for the cancellation of the Games over environmental, economic and other concerns — worries that Trump will require concessions in exchange for facilitating financial disbursements. This would mean at the least surrender to, and likely local assistance in, the administration's roundups of undocumented immigrants, as well as the banishment of homeless residents from prominent public spaces. 'We know he uses the power of the purse to try to bully and coerce to do what he wants on his larger agenda,' he says. 'It's, 'If you fight me, I'll punish you.' That's greater with the Olympics.' Trump is known to enjoy taking center stage at sports spectacles, from UFC bouts to the Super Bowl. Fox News commentator Jesse Watters, a reliable defender of the president, joked on-air in March that 'he's running out of events to go to,' noting, 'he's going to want to hold the torch in L.A.' NYU hospitality professor Christopher Gaffney, who has studied the Games, agrees, contending that Trump is likely to underscore his worldview at the opening ceremony: 'You know that [authoritarian world leaders] Milei, Bukele and Orbán will be in his presidential box.' Which is why key officials and outside Games observers alike believe that Trump wants the 2028 Olympics to triumph — if only on his terms. 'This is an opportunity for him to shine,' California Gov. Gavin Newsom said on NBC's Meet the Press in January. Adds Aronson, the USC professor, 'Presuming he doesn't try to run for a third term, this will be his swan song, and it's in his interest to put on a good show.' Mia Galuppo contributed to this report. This story appeared in the June 4 issue of The Hollywood Reporter magazine. Click here to subscribe. Best of The Hollywood Reporter Most Anticipated Concert Tours of 2025: Beyoncé, Billie Eilish, Kendrick Lamar & SZA, Sabrina Carpenter and More Hollywood's Most Notable Deaths of 2025 Hollywood's Highest-Profile Harris Endorsements: Taylor Swift, George Clooney, Bruce Springsteen and More

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store